



**GENPHARMASEC  
LIMITED**

CIN : L24231MH1992PLC323914

(Formerly known as Generic Pharmasec Limited)



Office No. 104 & 105 (1st Floor), Gundecha Industrial Premises,  
Co-Operative Society Ltd., Akurli Road, Kandivali (East),  
Mumbai, Maharashtra, 400101



+91- 86555 50242



compliance@genpharmasec.com  
info@genpharmasec.com



www.genpharmasec.com

**Date: 05.06.2023**

To,  
The Listing Compliance  
**BSE Ltd.**  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai- 400001

**BSE Scrip Code: 531592**

**Subject: Outcome of the Meeting of Board of Directors held on Monday, 5<sup>th</sup> June, 2023.**

Dear Sir/Ma'am,

Further to our intimation dated May 30, 2023 and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors ('Board') of the Company, at its meeting held on Monday, 5<sup>th</sup> June, 2023 situated at the registered office of the company discussed and approved the following:

1. The Board approved the issuance of Fully paid-up equity shares of face value of Rs. 1/- each of the Company on rights basis to eligible equity shareholders of the Company as on the record date (to be notified later), of an Issue size of upto Rs. 49 Crores (Rupees Forty-Nine Crores Only) (Rights Issue) in accordance with applicable laws, including the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("Rights Issue").
2. Further, the Board has constituted Rights Issue Committee and authorized its members to decide on the terms and conditions of the Issue, including but not limiting to the final issue size /amount, rights entitlement ratio, the issue price, record date, timing of the rights issue and approval of draft letter of offer; appointment of intermediaries, if required; allotment of shares and other related matters.
3. The Board Members has also approved the Draft Letter of Offer ("DLOF") for raising of funds through issuance and allotment of fully paid-up equity shares of Rs. 1/- each ("Equity Shares") to the eligible equity shareholders of the Company on a Rights basis, on such terms and at such price and ratio as may be decided by the Board (including Right Issue Committee) at a later date, as on the record date (to be notified later), for an amount upto Rs. 49 Crores (Rupees Forty-Nine Crores Only), subject to receipt of in-principle approval of BSE Limited, in accordance with the applicable laws including the provisions of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the Companies Act, 2013 and rules made there under, as amended from time to time ("Rights Issue").



Details pursuant to Regulation 30 and other relevant provisions of the SEBI Listing Regulations are enclosed as an Annexure I.

We further inform you that the Board Meeting commenced at 03:00 p.m today and concluded at 4.30 p.m.

Kindly take same on your records.


Thanking You.

For, **Genpharmasec Limited**

HETA  
DEEPAK  
SHAH

Digitally signed by  
HETA DEEPAK SHAH  
Date: 2023.06.05  
16:31:41 +05'30'

**Heta Shah**  
Company Secretary and  
Compliance Officer  
ACS No.: 69749



Date: 05.06.2023  
Place: Mumbai

### Annexure-I

The details as required under SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 with respect to the Right issue is given as under:

Particulars	Details
Type of securities proposed to be issued	Fully paid-up Equity Share of the face value of Rs. 1/- each of the Company
Type of issuance (further public offering, rights issue, depository receipts (ADR / GDR), qualified institutions placement, preferential allotment etc.);	Right issue to the existing shareholders
Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately);	Number of Equity Share and, in such ratio, as may be decided by the Board of Directors/Rights Issue committee for an Amount upto Rs. 49 Crores (Rupees Forty-Nine Crores Only).
Any cancellation or termination of proposal for issuance of Securities including reasons thereof.	N.A.

